Multiple sclerosis (Houndmills, Basingstoke, England)最新文献

{"title":"Frailty in multiple sclerosis: A closer look at the deficit accumulation framework.","authors":"Tobia Zanotto, Sharon G Lynch, Jeffrey M Hausdorff, Jacob J Sosnoff","doi":"10.1177/13524585211061332","DOIUrl":"https://doi.org/10.1177/13524585211061332","url":null,"abstract":"The growing availability and effectiveness of diseasemodifying therapies has increased the life expectancy of people living with multiple sclerosis (MS). Consequently, there is an emerging need to explore the impact of age-related conditions on health outcomes in this population. In this regard, the investigation of frailty, a biological syndrome of decreased reserve and resistance to stressors arising from cumulative declines across multiple physiologic systems, may offer valuable insights to improve our understanding of the challenges older people with MS may face, and thus allow us to optimize care and quality of life of people with MS. While many approaches to conceptualize and evaluate frailty exist, the frailty index (FI), based on the deficit accumulation framework,1 has often appealed to clinicians due to its adaptability and utility in routine care.","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"1000-1001"},"PeriodicalIF":5.8,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39743609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Absence of attack-independent neuroaxonal injury in MOG antibody-associated disease: Longitudinal assessment of serum neurofilament light chain.","authors":"Jae-Won Hyun,&nbsp;So Yeon Kim,&nbsp;Yeseul Kim,&nbsp;Na Young Park,&nbsp;Ki Hoon Kim,&nbsp;Su-Hyun Kim,&nbsp;Ho Jin Kim","doi":"10.1177/13524585211063756","DOIUrl":"https://doi.org/10.1177/13524585211063756","url":null,"abstract":"<p><p>To evaluate the occurrence of attack-independent neuroaxonal and astrocytic damage in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) levels were longitudinally measured in 102 sera using a single-molecule array assay. Sera from 15 adults with relapsing MOGAD with available longitudinal samples for the median 24-month follow-up and 26 age-/sex-matched healthy controls were analyzed. sNfL levels were significantly elevated in all clinical attacks, where the levels decreased below or close to cut-off value within 6 months after attacks. sNfL levels were consistently low during inter-attack periods. In contrast, sGFAP levels did not increase in most clinical attacks and remained low during follow-up. Significant neuroaxonal damage was observed at clinical attacks, while attack-independent neuroaxonal and astrocytic injury was absent in MOGAD.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"993-999"},"PeriodicalIF":5.8,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39771930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial.","authors":"Mary Rensel,&nbsp;Aram Zabeti,&nbsp;Maureen A Mealy,&nbsp;Daniel Cimbora,&nbsp;Dewei She,&nbsp;Jorn Drappa,&nbsp;Eliezer Katz","doi":"10.1177/13524585211047223","DOIUrl":"https://doi.org/10.1177/13524585211047223","url":null,"abstract":"<p><strong>Background: </strong>Efficacy and safety of inebilizumab for treatment of neuromyelitis optica spectrum disorder in adults seropositive for aquaporin-4 (AQP4)-immunoglobulin (Ig) G were demonstrated in the 28-week randomized controlled period of the N-MOmentum study.</p><p><strong>Objective: </strong>To assess efficacy and safety of long-term inebilizumab treatment.</p><p><strong>Methods: </strong>Post hoc analysis was performed in 75 AQP4-IgG-seropositive participants receiving inebilizumab for ⩾4 years in the randomized controlled period and open-label extension of the N-MOmentum study.</p><p><strong>Results: </strong>Eighteen attacks occurred in 13 participants during inebilizumab treatment (annualized attack rate, 0.052 attacks/person-year). Twelve attacks occurred during the first year of treatment, and two each occurred in years 2-4. Disability scores remained stable throughout ⩾4 years of treatment. Inebilizumab was well tolerated, with two (2.7%) serious treatment-emergent adverse events related to inebilizumab and no deaths. Immunoglobulin G levels decreased over time; however, correlation between severe infections and low IgG levels could not be determined because of their small numbers.</p><p><strong>Conclusion: </strong>These results from the N-MOmentum study continue to support use of inebilizumab for treatment of neuromyelitis optica spectrum disorder. Furthermore, the findings suggest that efficacy of inebilizumab may be enhanced after the first year of treatment, warranting additional long-term investigation.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"925-932"},"PeriodicalIF":5.8,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cc/b6/10.1177_13524585211047223.PMC9024030.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39500283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis Registry.","authors":"Stefan J Blaschke,&nbsp;David Ellenberger,&nbsp;Peter Flachenecker,&nbsp;Kerstin Hellwig,&nbsp;Friedemann Paul,&nbsp;Dieter Pöhlau,&nbsp;Christoph Kleinschnitz,&nbsp;Paulus S Rommer,&nbsp;Maria A Rueger,&nbsp;Uwe K Zettl,&nbsp;Alexander Stahmann,&nbsp;Clemens Warnke","doi":"10.1177/13524585211039753","DOIUrl":"https://doi.org/10.1177/13524585211039753","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the time to diagnosis in multiple sclerosis (MS) in Germany.</p><p><strong>Methods: </strong>Analysis of real-world registry data from the German Multiple Sclerosis Registry (GMSR) and performing a primary analysis in patients where month-specific registration of the dates of onset and diagnosis was available.</p><p><strong>Results: </strong>As of January 2020, data of a total of 28,658 patients with MS were extracted from the GMSR, with 9836 patients included in the primary analysis. The mean time to diagnosis was shorter following the introduction of the first magnetic resonance imaging (MRI)-based McDonald criteria in 2001. This effect was most pronounced in younger adults below the age of 40 years with relapsing onset multiple sclerosis (ROMS), with a decrease from 1.9 years in 2010 to 0.9 years in 2020, while unchanged in patients aged 40-50 years (1.4 years in 2010 and 1.3 years in 2020). In the limited number of paediatric onset MS patients, the time to diagnosis was longer and did not change (2.9 years).</p><p><strong>Conclusion: </strong>The current sensitive MRI-based diagnostic criteria have likely contributed to an earlier diagnosis of MS in Germany in younger adults aged 18-39 years with ROMS. Whether this translated to earlier initiation of disease-modifying treatment or had a beneficial effect on patient outcomes remains to be demonstrated.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"865-871"},"PeriodicalIF":5.8,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39357820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epilepsy as a predictor of disease progression in multiple sclerosis.","authors":"Matthias Grothe,&nbsp;David Ellenberger,&nbsp;Felix von Podewils,&nbsp;Alexander Stahmann,&nbsp;Paulus S Rommer,&nbsp;Uwe K Zettl","doi":"10.1177/13524585211046739","DOIUrl":"https://doi.org/10.1177/13524585211046739","url":null,"abstract":"<p><strong>Background: </strong>Epilepsy development during the course of multiple sclerosis (MS) is considered to be the result of cortical pathology. However, no long-term data exist on whether epilepsy in MS also leads to increasing disability over time.</p><p><strong>Objective: </strong>To examine if epilepsy leads to more rapid disease progression.</p><p><strong>Methods: </strong>We analyzed the data of 31,052 patients on the German Multiple Sclerosis Register in a case-control study.</p><p><strong>Results: </strong>Secondary progressive disease course (odds ratio (OR) = 2.23), age (OR = 1.12 per 10 years), and disability (OR = 1.29 per Expanded Disability Status Scale (EDSS) point) were associated with the 5-year prevalence of epilepsy. Patients who developed epilepsy during the course of the disease had a higher EDSS score at disease onset compared to matched control patients (EDSS 2.0 vs 1.5), progressed faster in each dimension, and consequently showed higher disability (EDSS 4.4 vs 3.4) and lower employment status (40% vs 65%) at final follow-up. After 15 years of MS, 64% of patients without compared to 54% of patients with epilepsy were not severely limited in walking distance.</p><p><strong>Conclusion: </strong>This work highlights the association of epilepsy on disability progression in MS, and the need for additional data to further clarify the underlying mechanisms.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"942-949"},"PeriodicalIF":5.8,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39475984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study.","authors":"Igal Rosenstein,&nbsp;Markus Axelsson,&nbsp;Lenka Novakova,&nbsp;Kaj Blennow,&nbsp;Henrik Zetterberg,&nbsp;Jan Lycke","doi":"10.1177/13524585211039104","DOIUrl":"https://doi.org/10.1177/13524585211039104","url":null,"abstract":"<p><strong>Background: </strong>Neurofilament light (NFL) has been increasingly recognized for prognostic and therapeutic decisions.</p><p><strong>Objective: </strong>To validate the utility of cerebrospinal fluid NFL (cNFL) as a biomarker in clinical practice of relapsing-remitting multiple sclerosis (RRMS).</p><p><strong>Methods: </strong>RRMS patients (<i>n</i> = 757) who had cNFL analyzed as part of the diagnostic work-up in a single academic multiple sclerosis (MS) center, 2001-2018, were retrospectively identified. cNFL concentrations were determined with two different immunoassays and the ratio of means between them was used for normalization.</p><p><strong>Results: </strong>RRMS with relapse had 4.4 times higher median cNFL concentration (1134 [interquartile range (IQR) 499-2744] ng/L) than those without relapse (264 [125-537] ng/L, <i>p</i> < 0.001) and patients with gadolinium-enhancing lesions had 3.3 times higher median NFL (1414 [606.8-3210] ng/L) than those without (426 [IQR 221-851] ng/L, <i>p</i> < 0.001). The sensitivity and specificity of cNFL to detect disease activity was 75% and 98.5%, respectively. High cNFL at MS onset predicted progression to Expanded Disability Status Scale (EDSS) ⩾ 3 (<i>p</i> < 0.001, hazard ratios (HR) = 1.89, 95% CI = 1.44-2.65) and conversion to secondary progressive MS (SPMS, <i>p</i> = 0.001, HR = 2.5, 95% CI = 1.4-4.2).</p><p><strong>Conclusions: </strong>cNFL is a robust and reliable biomarker of disease activity, treatment response, and prediction of disability and conversion from RRMS to SPMS. Our data suggest that cNFL should be included in the assessment of patients at MS-onset.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"872-884"},"PeriodicalIF":5.8,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024026/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39311341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brighter spotty lesions on spinal MRI help differentiate AQP4 antibody-positive NMOSD from MOGAD.","authors":"Jae-Won Hyun,&nbsp;Hye Lim Lee,&nbsp;Jaehong Park,&nbsp;Jiah Kim,&nbsp;Ju-Hong Min,&nbsp;Byoung Joon Kim,&nbsp;Seung Woo Kim,&nbsp;Ha Young Shin,&nbsp;So-Young Huh,&nbsp;Woojun Kim,&nbsp;Ji Won Seo,&nbsp;Ki Hoon Kim,&nbsp;Su-Hyun Kim,&nbsp;Ho Jin Kim","doi":"10.1177/13524585211060326","DOIUrl":"https://doi.org/10.1177/13524585211060326","url":null,"abstract":"<p><p>In a large acute myelitis cohort, we aimed to determine whether brighter spotty lesions (BSLs)-using the refined terminology-on spinal magnetic resonance imaging (MRI) help distinguish aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) from myelin oligodendrocyte glycoprotein antibody disease (MOGAD). An experienced neuro-radiologist and two neurologists independently analyzed 133 spinal MRI scans (65 from MOGAD and 68 from AQP4-NMOSD) acquired within 1 month of attacks. BSLs were observed in 18 of 61 (30%) participants with AQP4-NMOSD, while none of 49 participants with MOGAD showed BSL (<i>p</i> < 0.001). BSL during the acute phase would be useful to differentiate AQP4-NMOSD from MOGAD.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"989-992"},"PeriodicalIF":5.8,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39805332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers.","authors":"Matthias Bussas,&nbsp;Sophia Grahl,&nbsp;Viola Pongratz,&nbsp;Achim Berthele,&nbsp;Christiane Gasperi,&nbsp;Till Andlauer,&nbsp;Christian Gaser,&nbsp;Jan S Kirschke,&nbsp;Benedikt Wiestler,&nbsp;Claus Zimmer,&nbsp;Bernhard Hemmer,&nbsp;Mark Mühlau","doi":"10.1177/13524585211044957","DOIUrl":"https://doi.org/10.1177/13524585211044957","url":null,"abstract":"<p><strong>Background: </strong>Lesions of brain white matter (WM) and atrophy of brain gray matter (GM) are well-established surrogate parameters in multiple sclerosis (MS), but it is unclear how closely these parameters relate to each other.</p><p><strong>Objective: </strong>To assess across the whole cerebrum whether GM atrophy can be explained by lesions in connecting WM tracts.</p><p><strong>Methods: </strong>GM images of 600 patients with relapsing-remitting MS (women = 68%; median age = 33.0 years, median expanded disability status scale score = 1.5) were converted to atrophy maps by data from a healthy control cohort. An atlas of WM tracts from the Human Connectome Project and individual lesion maps were merged to identify potentially disconnected GM regions, leading to individual disconnectome maps. Across the whole cerebrum, GM atrophy and potentially disconnected GM were tested for association both cross-sectionally and longitudinally.</p><p><strong>Results: </strong>We found highly significant correlations between disconnection and atrophy across most of the cerebrum. Longitudinal analysis demonstrated a close temporal relation of WM lesion formation and GM atrophy in connecting fibers.</p><p><strong>Conclusion: </strong>GM atrophy is associated with WM lesions in connecting fibers. Caution is warranted when interpreting group differences in GM atrophy exclusively as differences in early neurodegeneration independent of WM lesion formation.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"900-909"},"PeriodicalIF":5.8,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024016/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39472130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optical coherence tomography angiography indicates subclinical retinal disease in neuromyelitis optica spectrum disorders.","authors":"Lilian Aly,&nbsp;Eva-Maria Strauß,&nbsp;Nikolaus Feucht,&nbsp;Isabella Weiß,&nbsp;Achim Berthele,&nbsp;Meike Mitsdoerffer,&nbsp;Christian Haass,&nbsp;Bernhard Hemmer,&nbsp;Mathias Maier,&nbsp;Thomas Korn,&nbsp;Benjamin Knier","doi":"10.1177/13524585211028831","DOIUrl":"https://doi.org/10.1177/13524585211028831","url":null,"abstract":"Background: Neuromyelitis optica spectrum disorders (NMOSD) are neuroinflammatory diseases of the central nervous system. Patients suffer from recurring relapses and it is unclear whether relapse-independent disease activity occurs and whether this is of clinical relevance. Objective: To detect disease-specific alterations of the retinal vasculature that reflect disease activity during NMOSD. Methods: Cross-sectional analysis of 16 patients with NMOSD, 21 patients with relapsing-remitting multiple sclerosis, and 21 healthy controls using retinal optical coherence tomography (OCT), optical coherence tomography angiography (OCT-A), measurement of glial fibrillary acidic protein (GFAP) serum levels, and assessment of visual acuity. Results: Patients with NMOSD but not multiple sclerosis revealed lower foveal thickness (FT) (p = 0.02) measures and an increase of the foveal avascular zone (FAZ) (p = 0.02) compared to healthy controls independent to optic neuritis. Reduced FT (p = 0.01), enlarged FAZ areas (p = 0.0001), and vessel loss of the superficial vascular complex (p = 0.01) were linked to higher serum GFAP levels and superficial vessel loss was associated with worse visual performance in patients with NMOSD irrespective of optic neuritis. Conclusion: Subclinical parafoveal retinal vessel loss might occur during NMOSD and might be linked to astrocyte damage and poor visual performance. OCT-A may be a tool to study subclinical disease activity during NMOSD.","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"522-531"},"PeriodicalIF":5.8,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961243/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39182467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A smartphone sensor-based digital outcome assessment of multiple sclerosis.","authors":"Xavier Montalban,&nbsp;Jennifer Graves,&nbsp;Luciana Midaglia,&nbsp;Patricia Mulero,&nbsp;Laura Julian,&nbsp;Michael Baker,&nbsp;Jan Schadrack,&nbsp;Christian Gossens,&nbsp;Marco Ganzetti,&nbsp;Alf Scotland,&nbsp;Florian Lipsmeier,&nbsp;Johan van Beek,&nbsp;Corrado Bernasconi,&nbsp;Shibeshih Belachew,&nbsp;Michael Lindemann,&nbsp;Stephen L Hauser","doi":"10.1177/13524585211028561","DOIUrl":"https://doi.org/10.1177/13524585211028561","url":null,"abstract":"<p><strong>Background: </strong>Sensor-based monitoring tools fill a critical gap in multiple sclerosis (MS) research and clinical care.</p><p><strong>Objective: </strong>The aim of this study is to assess performance characteristics of the Floodlight Proof-of-Concept (PoC) app.</p><p><strong>Methods: </strong>In a 24-week study (clinicaltrials.gov: NCT02952911), smartphone-based active tests and passive monitoring assessed cognition (electronic Symbol Digit Modalities Test), upper extremity function (Pinching Test, Draw a Shape Test), and gait and balance (Static Balance Test, U-Turn Test, Walk Test, Passive Monitoring). Intraclass correlation coefficients (ICCs) and age- or sex-adjusted Spearman's rank correlation determined test-retest reliability and correlations with clinical and magnetic resonance imaging (MRI) outcome measures, respectively.</p><p><strong>Results: </strong>Seventy-six people with MS (PwMS) and 25 healthy controls were enrolled. In PwMS, ICCs were moderate-to-good (ICC(2,1) = 0.61-0.85) across tests. Correlations with domain-specific standard clinical disability measures were significant for all tests in the cognitive (<i>r</i> = 0.82, <i>p</i> < 0.001), upper extremity function (|r|= 0.40-0.64, all <i>p</i> < 0.001), and gait and balance domains (<i>r</i> = -0.25 to -0.52, all <i>p</i> < 0.05; except for Static Balance Test: <i>r</i> = -0.20, <i>p</i> > 0.05). Most tests also correlated with Expanded Disability Status Scale, 29-item Multiple Sclerosis Impact Scale items or subscales, and/or normalized brain volume.</p><p><strong>Conclusion: </strong>The Floodlight PoC app captures reliable and clinically relevant measures of functional impairment in MS, supporting its potential use in clinical research and practice.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"654-664"},"PeriodicalIF":5.8,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c0/c7/10.1177_13524585211028561.PMC8961252.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39182877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}